Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$50.6 million.

  • Prime Medicine's Net Income towards Common Stockholders rose 368.64% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 999.32%. This contributed to the annual value of -$195.9 million for FY2024, which is 113.61% up from last year.
  • Latest data reveals that Prime Medicine reported Net Income towards Common Stockholders of -$50.6 million as of Q3 2025, which was up 368.64% from -$52.6 million recorded in Q2 2025.
  • Prime Medicine's Net Income towards Common Stockholders' 5-year high stood at -$22.8 million during Q3 2021, with a 5-year trough of -$69.3 million in Q4 2021.
  • For the 5-year period, Prime Medicine's Net Income towards Common Stockholders averaged around -$46.1 million, with its median value being -$45.8 million (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 4139.56% in 2022, then tumbled by 6169.42% in 2023.
  • Quarter analysis of 5 years shows Prime Medicine's Net Income towards Common Stockholders stood at -$69.3 million in 2021, then skyrocketed by 41.4% to -$40.6 million in 2022, then tumbled by 61.69% to -$65.6 million in 2023, then soared by 35.6% to -$42.3 million in 2024, then decreased by 19.65% to -$50.6 million in 2025.
  • Its last three reported values are -$50.6 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.